These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 21683411)

  • 1. Re: Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. O. Celhay, M. Yacoub, J. Irani, B. Dore, O. Cussenot and G. Fromont. J Urol 2010; 184: 2172-2178.
    Zhang M
    J Urol; 2011 Aug; 186(2):756. PubMed ID: 21683411
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression.
    Celhay O; Yacoub M; Irani J; Dore B; Cussenot O; Fromont G
    J Urol; 2010 Nov; 184(5):2172-8. PubMed ID: 20850840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8.
    Sharma R; Sundar S
    Eur Urol; 2007 Apr; 51(4):1146. PubMed ID: 17161523
    [No Abstract]   [Full Text] [Related]  

  • 4. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-58.
    Pitts WR
    Eur Urol; 2007 Mar; 51(3):864. PubMed ID: 16860461
    [No Abstract]   [Full Text] [Related]  

  • 6. Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: a review.
    Westin P; Bergh A
    Cancer Detect Prev; 1998; 22(5):476-84. PubMed ID: 9727630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Hendrik Isbarn, Jehonathan H. Pinthus, Leonard S. Marks, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009;56:48-56.
    Friedman AE
    Eur Urol; 2009 Nov; 56(5):e23; author reply e24. PubMed ID: 19586711
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Russell Szmulewitz, Supriya Mohile, Edwin Posadas, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009;56:97-104.
    Friedman AE
    Eur Urol; 2009 Nov; 56(5):e36; author reply e37. PubMed ID: 19683856
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer.
    Castilla C; Congregado B; Conde JM; Medina R; Torrubia FJ; Japón MA; Sáez C
    Urology; 2010 Oct; 76(4):1017.e1-6. PubMed ID: 20708221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
    Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
    Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Re: "Current role of chemotherapy in the treatment of hormone-resistant metastatic prostate cancer" by Xavier Breton, Eric Lechevallier, Christian Coulange, Prog. Urol., 2005, 15, 398-404].
    Berdah JF
    Prog Urol; 2005 Dec; 15(6):1160. PubMed ID: 16429675
    [No Abstract]   [Full Text] [Related]  

  • 12. Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.
    Mäki HE; Saramäki OR; Shatkina L; Martikainen PM; Tammela TL; van Weerden WM; Vessella RL; Cato AC; Visakorpi T
    J Pathol; 2007 Aug; 212(4):395-401. PubMed ID: 17503439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter to the Editor; Re: Wirth MP, Weissbach L, Marx F-J, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Hinke A, Froehner M. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45:267-70.
    Rocco B; Matei DV; de Cobelli O; Rocco F
    Eur Urol; 2004 Aug; 46(2):272-3; author reply 273. PubMed ID: 15245825
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leupoprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-8.
    Koupparis AJ
    Eur Urol; 2006 Sep; 50(3):626-7. PubMed ID: 16750291
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy in hormone refractory prostate cancer: where do we stand?
    Clarke NW; Wylie JP
    Eur Urol; 2004 Dec; 46(6):709-11. PubMed ID: 15548436
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. T. Kurahashi, H. Miyake, I. Hara and M. Fujisawa J Urol 2007; 177: 757-761.
    Vale S
    J Urol; 2007 Jul; 178(1):352-3. PubMed ID: 17507039
    [No Abstract]   [Full Text] [Related]  

  • 17. [Expression of androgen receptor protein in hormone refractory prostate cancer].
    Zhang Y; Chen W; Hu XK; Gui ZN
    Ai Zheng; 2003 Jan; 22(1):95-7. PubMed ID: 12561446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Per-Anders Abrahamsson. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57:49-59.
    Drewa T
    Eur Urol; 2010 Jul; 58(1):e4; author reply e5-6. PubMed ID: 20363067
    [No Abstract]   [Full Text] [Related]  

  • 19. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.